Celcuity

Scientific Posters & Publications

Drug development backed by sound research

Below are a sample of innovative research published and presented by our team and our collaborators.

Filter by Cancer Type:

2020
Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

Stefano Rossetti, Catherine Kuzmicki, Aaron Broege, Joanna Sabat, Salmaan Khan, Ian MacNeil, Brian Sullivan, Lance Laing

2020 American Association of Cancer Research (AACR)
2020
Test measuring signaling activity in live patient tumor cells identifies PI3KCA WT patients who may benefit from PIK3 inhibitors

Lance G Laing, Salmaan Khan, Ian A MacNeil, Catherine Kuzmicki, Benjamin Rich, Abhay Shukla, Kelly Brass, Brian Sullivan

2020 American Society of Clinical Oncology (ASCO)
2020
New HER2‐negative breast cancer subtype responsive to anti‐HER2 therapy identified. Journal of Cancer Research and Clinical Oncology 2020;146:605-619

Ian A. MacNeil, David J. Burns, Benjamin E. Rich, Sajjad M. Soltani, Samantha Kharbush, Nicole G. Osterhaus, Brian F. Sullivan, Douglas M. Hawkins, Jodie R. Pietruska, Lance G. Laing

Journal of Cancer Research and Clinical Oncology
2019
Sub-Group of PIK3CA WT breast cancer patients have hyperactive S1P and LPA signaling tumors responsive to PI3K inhibitors: functional signaling test identifies new patient group who may benefit from PI3K inhibitors

Lance G Laing, Salmaan Khan, Ian A MacNeil, Catherine Kuzmicki, Samantha Kharbush, Benjamin Rich, Abhay Shukla, Kelly Brass, Brian Sullivan

2019 San Antonio Breast Cancer Symposium (SABCS)
2018
Evaluation of pan-HER and c-MET inhibitors tested ex vivo in live primary HER2- breast cancer cells with hyperactive c-MET and ErbB family signaling

Laing, L., Burns, D., Khan, S., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Kharbush, S., Broege, AM., Brass, K., Mutka, S., Sullivan. B

2018 San Antonio Breast Cancer Symposium (SABCS)
2018
Evaluating contribution of hyperactive c-Met and ErbB signaling to tumor progression in mouse breast tumor xenografts: an in vivo study of c-Met and ErbB targeted therapies

Laing, L., Burns, D., Khan, S., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Kharbush, S., Brass, K., Sullivan. B

2018 San Antonio Breast Cancer Symposium (SABCS)
2018
Sub-group of HER2- breast cancer patients with hyperactive and co-involved c-Met and ErbB pathways identified: functional signal profiling test identifies patient group that may benefit from c-Met and pan-HER combination therapy

Laing, L., Burns, D., Khan, S., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Kharbush, S., Brass, K., Broege, AM., Mutka, S., Sullivan. B

2018 San Antonio Breast Cancer Symposium (SABCS)
2018
Live tumor cell functional analysis and a xenograft model find co-activated c-Met and ErbB signaling in HER2-negative breast cancer

Lance G Laing, David J Burns, Salmaan Khan, Ian A MacNeil, Benjamin E Rich, Sajjad M. Soltani, Samantha Myhre, Brian F Sullivan

2018 American Society of Clinical Oncology (ASCO)
2018
A phase 2 study of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in HER2-negative breast cancer patients with abnormal HER2-driven signaling transduction (NCT03412643)

Eleftherios P. Mamounas, MD, MPH; Lance G Laing

2018 Miami Breast Cancer Conference
2017
Use of a functional signal profiling test to determine the prevalence of abnormal HER2-driven signaling activity in the HER2-negative breast cancer patient population: New patient group may benefit from anti-HER2 therapy

Lance G Laing, David J Burns, Ian A MacNeil, Benjamin E Rich, Sajjad M Soltani, Samantha Myhre, Brian F Sullivan

2017 San Antonio Breast Cancer Symposium (SABCS)
2017
A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormal amplified HER2 signaling activity. Oncotarget. 2016 Oct 5;7(48) 78577-78590

Huang, Y., Burns, D., Rich, B., MacNeil, I., Dandapat, A., Soltani, S., Myhre, S., Sullivan, B., Furcht, L., Lange, C., Hurvitz, S., & Laing, L.

Oncotarget
2017
Measuring functional HER2-driven signaling status ex vivo to predict response to HER2 therapy: Results from a mouse breast tumor xenograft study

Laing, L., Burns, D., Huang, Y., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Sullivan, B.

2017 American Society of Clinical Oncology (ASCO)
2017
Development of a test that measures real-time HER2 signaling activity in live breast cancer cell lines and primary cells. BMC Cancer. 2017 March 17:199

Huang, Y., Burns, D., Rich, B., MacNeil, I., Dandapat, A., Soltani, S., Myhre, S., Sullivan, B., Lange, C., Furcht, L., Laing, L.

BMC Cancer
2017
Inhibition of abnormal HER2-driven signaling by two HER2 targeted antibody drugs tested ex vivo in live primary HER2- breast cancer cell samples and HER2+ cell lines

2017 Miami Breast Cancer Conference
2016
Quantification of HER2-driven signaling (HER2S) inhibition of four different anti-HER2 drugs tested ex vivo in live primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity

Laing, L., Burns, D., Huang, Y., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Sullivan, B.

2016 San Antonio Breast Cancer Symposium (SABCS)